What Magnesiocard Treats: Main Uses and Benefits

Magnesiocard is generally used to address and provide symptomatic relief from manifestations directly linked to a confirmed magnesium deficiency (hypomagnesemia). It is applied across domains where additional symptomatic support is needed for conditions where symptoms may intensify temporarily due to low magnesium levels.

The medication is relevant for easing challenging symptoms associated with deficiency, including involuntary muscle contractions (cramps and spasms), generalized weakness, and pronounced nervousness. The use of oral magnesium salts is considered relevant in clinical settings that involve acute or unstable symptom patterns. The therapy provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.

“Magnesiocard is applied in clinical settings that involve acute or disruptive symptom patterns from involuntary muscle contractions.”

Focus on Symptomatic Relief

Magnesiocard is commonly used to help with symptoms related to physical discomfort and increased neurological or muscular activity, helping to manage symptoms that interfere with daily functioning.

Regulatory References

1. Medicines and Healthcare products Regulatory Agency (MHRA) assessment report for Magnaspartate

Who can and cannot use Magnesiocard?

Eligibility for Magnesiocard is defined by regulatory bodies based primarily on organ function and established safety in specific age groups.

Classification	Population/Condition
Absolute Contraindication	Severe renal impairment (typically GFR < 30 mL/min)
	Pre-existing hypermagnesaemia (high magnesium levels)
	Hypersensitivity to Magnesium L-aspartate or excipients
	Disorders of cardiac conduction (e.g., bradycardia)
Conditional Use/Caution	Mild to moderate renal impairment (requires serum magnesium monitoring)
	Diabetes mellitus (due to excipient content in some forms)
Use Not Established	Children under 2 years of age

---

The medicine is contraindicated in patients with severe renal impairment because the kidneys are responsible for magnesium excretion, leading to a high risk of accumulation and potential toxicity. Use in children aged 2 years and above is generally established for the oral solution/granules formulation, but it is not established below this age threshold. Use is permitted for correcting documented deficiency during both pregnancy and breastfeeding.

Interactions with other medicines and products

Regulatory documentation confirms that Magnesiocard (Magnesium aspartate) has officially documented interaction patterns primarily concerning its absorption profile and potential for systemic accumulation. The preparation is contraindicated in patients with severe renal impairment (GFR less than 30 mL/min) due to the high risk of magnesium accumulation and subsequent intoxication.

---

Pharmacokinetic Interactions (Reduced Absorption)

Magnesium acts as a divalent cation, physically binding to certain co-administered oral medicines in the digestive tract. This chelation process results in a pharmacokinetic interaction that reduces the systemic exposure of the interacting drug. Medicinal products officially identified in regulatory documents as being affected include oral tetracycline and fluoroquinolone antibiotics, oral bisphosphonates (e.g., alendronic acid), and levothyroxine.

Timing Requirement: To mitigate this reduction in drug concentration, a mandatory time separation of at least two to three hours must be observed between the administration of Magnesiocard and the affected medicines.

---

Pharmacodynamic Interactions

An additive pharmacodynamic effect is documented when Magnesiocard is co-administered with other magnesium-containing preparations, such as certain antacids or laxatives. This combination significantly increases the overall serum magnesium load and the risk of developing hypermagnesemia. Furthermore, concurrent use with neuromuscular blocking agents may enhance the therapeutic effect of the blocker, risking increased neuromuscular blockade. Patients with existing renal impairment are at a heightened risk for this additive toxicity due to impaired renal excretion.

The mechanism of action of Magnesiocard is entirely attributed to the delivery of the essential magnesium ion ( Mg^2+), which functions as a core electrolyte modulator and enzymatic cofactor. The pharmacological effect centers on three primary mechanistic domains.

Cellular Energy and Metabolic Stabilization

Mg^2+ serves as a cofactor for over 300 enzyme systems, including the critical Na^+/ K^+-ATPase (Sodium-Potassium Pump). Mg^2+ is required to form the bioactive Mg-ATP complex, which powers cellular functions. This mechanism facilitates the maintenance of cell function and modulates biological processes associated with excessive excitability.

Neuromuscular Signaling Modulation

Mg^2+ acts as a dual modulator of neural transmission. It is a physical blocker of the Ca^2+ channel in the NMDA receptor centrally, and peripherally, it inhibits the release of the excitatory neurotransmitter acetylcholine at the nerve terminal. This combined action modulates nerve-to-muscle signaling, decreasing the velocity of neuromuscular transmission.

Physiological Calcium Antagonism

The magnesium ion acts as a functional antagonist to calcium ( Ca^2+) by competing for binding sites on cell membranes and smooth muscle structures. By reducing the effective availability of Ca^2+ for contraction signaling, this mechanism promotes relaxation of smooth muscle tissues and modulates electrolyte flux.

Official Administration Guidelines

Magnesiocard (magnesium aspartate) is intended for oral use and is available in forms such as powder for oral solution (granules) and tablets. The preparation is always dosed according to its elemental magnesium content, typically expressed in millimoles (mmol) or milligrams (mg).

---

Feature	Official Instruction Summary
Dosing Schedule	The daily dose for adults typically ranges from 10 mmol to 24 mmol of elemental magnesium. This is achieved through divided doses, such as 1 to 2 sachets (10 mmol strength) or multiple tablets, taken 1–3 times per day.
Timing in Relation to Meals	The medication should be administered before meals, as this timing may increase absorption.
Preparation Requirements	The contents of the powder sachet must be fully dissolved in a liquid such as water, tea, or fruit juice before being consumed. The dissolved solution can also be administered via a gastric, duodenal, or nasal feeding tube.
Age-Group Rules	Older adults typically require no dose adjustment. Specific, lower dosage schedules are provided for children and adolescents based on age and elemental magnesium content.
Missed Dose Rule	If a dose is forgotten, patients are instructed not to take a double dose to compensate.
Treatment Duration	The oral treatment should be continued for a minimum period of at least four weeks and may be suitable for long-term use with normal renal function.
Procedural Constraint	A time interval of 2 to 4 hours must be respected between taking this preparation and certain other medicines (e.g., iron, bisphosphonates) to avoid impaired absorption.

---

These guidelines establish a standardized procedural framework for using the preparation. This framework dictates the amount to be taken based on elemental content, ensures the necessary temporal constraint (before meals) is followed, and mandates the physical preparation steps (dissolution) for correct administration, all of which must be maintained over the required minimum duration.

Research Evidence for Correcting Magnesium Deficiency

The evidence base for using oral magnesium relies on a comprehensive review of established literature and early clinical and observational studies. Research examined the systemic and functional imbalance caused by low magnesium, specifically monitoring changes in biomarker levels and the ability to raise and sustain magnesium levels in the body. The evidence base was assessed by regulators, resulting in authorization being granted based on the existing body of scientific literature on magnesium salts generally. The main limitation is that approval relies on the general efficacy of oral magnesium salts, meaning there is limited information for long-term outcomes from studies conducted solely on this specific formulation.

Clinical Studies on Muscle Cramp Relief

Research exploring the usefulness of magnesium for muscle cramps was evaluated in short-term Randomized Controlled Trials (RCTs) and meta-analyses. These studies monitored patient-reported outcomes for changes in cramp frequency and intensity. Findings for idiopathic rest cramps were mixed; some trials described small reductions while others reported negligible changes. Similarly, evidence for pregnancy-associated rest cramps, derived from a small number of RCTs, also had conflicting results, and certainty remains low due to this inconsistency.

Evidence in Specific Patient Groups

In the context of deficiency treatment, the preparation was studied for patient groups including adults and children (aged two years and above). For symptomatic uses, studies concerning idiopathic rest cramps primarily examined older adults, meaning the results apply only to those populations. Data for other groups, such as younger individuals or those with exercise-associated cramps, remain insufficient.

Areas of Uncertainty and Research Gaps

Key research gaps exist primarily because no new, large-scale RCTs were specifically conducted on this particular product for deficiency treatment. Additionally, for symptomatic uses, the evidence quality varies across studies, with findings being mixed and subgroup results uncertain. For all areas, follow-up durations were limited, and long-term effects are not fully established based on the current body of evidence.

Key Studies & References

1. magnesium aspartate dihydrate (Magnaspartate®) - All Wales Therapeutics and Toxicology Centre (AWMSG Advice)
2. Product Update: magnesium aspartate dihydrate (Magnaspartate®) - Scottish Medicines Consortium (SMC) Advice

Common questions about Magnesiocard (FAQ)

Q: Is Magnesiocard the same as other magnesium supplements?

According to official product information, Magnesiocard contains magnesium aspartate, which is described as a synthetic organic salt. This specific form is described as having high oral bioavailability and is associated with potentially more effective absorption compared to common, less soluble inorganic magnesium forms.

Q: Why do doctors recommend Magnesiocard instead of just regular magnesium?

The official documentation describes the preparation as having high oral bioavailability. This means the mineral is potentially absorbed more effectively by the body when compared to other less soluble, inorganic types of magnesium. The formulation is designed to support the delivery of the active ingredient.

Q: Is Magnesiocard used for heart problems?

Studies and official information indicate that the active ingredient, magnesium, plays a role in regulating heart muscle function and stabilizing cardiac rhythm. However, regulatory documents state that the medicine is contraindicated (should not be used) in patients with pre-existing disorders of cardiac conduction.

Q: How long does it typically take for Magnesiocard to start working?

Pharmacokinetic studies indicate that the concentration of magnesium in the serum typically reaches its highest level approximately two to three hours after oral administration. Regulatory guidelines state the minimum period for oral treatment to be considered is at least four weeks.

Q: Can I take Magnesiocard with my daily multivitamin?

Official information describes that magnesium can bind to certain oral medicines in the digestive tract, which might reduce the absorption of the co-administered medicine. To help reduce the possibility of this effect, an interval of two to four hours must be respected between Magnesiocard and the administration of certain other medications.

Q: Can I crush or chew Magnesiocard tablets?

The official instructions for the powder formulation explicitly state that the contents must be fully dissolved in a liquid before consumption. The specific preparation instructions provided for the particular formulation (tablet, powder, or effervescent) define the correct method of administration.

Q: Does Magnesiocard affect sleep or energy levels?

The active ingredient's mechanism of action is directly related to supporting cellular energy and neuromuscular system functions. Regarding side effects, fatigue is listed in regulatory documents as a very rare reaction associated with long-term use and potentially elevated magnesium levels.

Q: What is the difference between Magnesiocard and magnesium oxide?

Magnesiocard contains magnesium aspartate, which is an organic salt structure. This form is clinically recognized for its high oral bioavailability and is associated with potentially more effective absorption compared to less soluble inorganic magnesium forms, such as magnesium oxide.

Q: What if I'm taking multiple other supplements, should I still take Magnesiocard?

Regulatory documents include a warning regarding an additive effect when Magnesiocard is taken concurrently with other magnesium-containing preparations, such as certain antacids or laxatives. This combination may lead to an increased risk of hypermagnesemia (high magnesium levels).

Q: Are there specific symptoms that mean I should stop taking Magnesiocard immediately?

The official documents describing symptoms of very high magnesium levels (intoxication) include a significant fall in blood pressure, nausea, vomiting, hyporeflexia, and potential effects on the heart or breathing. These symptoms are officially described as signs of magnesium intoxication (overdose).

Q: Is Magnesiocard described as a preventative or a treatment medicine?

The general purpose of the preparation, as described in official documents, is focused on correcting magnesium deficiency (Hypomagnesemia) and managing associated symptoms, such as mild neuromuscular disturbances.

Q: Does Magnesiocard interact with blood pressure medication?

Magnesium is known to function as a physiological calcium antagonist. Regulatory information notes that concurrent use with neuromuscular blocking agents may enhance the blocker's effect. Diuretic medications, which are common for blood pressure control, may also affect the body's magnesium balance.

Q: Can people with low blood pressure take Magnesiocard?

Official documents list that symptoms of magnesium intoxication (very high levels) include a significant fall in blood pressure. Additionally, the medicine is formally contraindicated if the patient has certain pre-existing disorders of cardiac conduction.

Q: Does Magnesiocard have an expiration date I should worry about?

Yes, official documents provide instructions for the storage and proper disposal of any unused or expired product. They also detail the limited stability period for the dissolved solution once it is prepared.

Q: Are there any known issues with Magnesiocard and caffeine consumption?

Regulatory reviews of magnesium metabolism indicate that consumption of factors such as caffeine and alcohol may contribute to lower magnesium retention in the body.

Q: Is Magnesiocard used for anxiety or stress relief?

The preparation’s general purpose is to correct magnesium deficiency. The active ingredient plays a key role in neuromuscular signaling modulation, and symptoms of deficiency often include irritability, which links to the body's physiological stress response.

Q: Can I take Magnesiocard while drinking alcohol?

Regulatory reviews suggest that alcohol consumption acts as a diuretic for magnesium. This means that alcohol is a factor that can potentially lead to lower magnesium retention in the body.

Magnesiocard (magnesium aspartate) must be stored and disposed of according to strict regulatory requirements to maintain product integrity and environmental safety.

Official Storage Conditions

Requirement	Specific Rule
Temperature Restriction	Do not store the unopened powder above 25 C.
Reconstituted Solution Stability	Must be used immediately or within 24 hours when dissolved in bottled water and stored below 25 C.
Child Safety	Keep this medicine out of the sight and reach of children.

Official Disposal Rules

Disposal must comply with local waste requirements. The medicine must not be thrown away via wastewater or household waste. Patients are instructed to consult a pharmacist for guidance on how to properly dispose of any unused or expired product.